Hisamitsu Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Kazuhide Nakatomi

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	9yrs
CEO ownership	0.3%
Management average tenure	6yrs
Board average tenure	10yrs

Recent management updates

Recent updates

CEO

Kazuhide Nakatomi (51 yo)

9yrs

Tenure

Mr. Kazuhide Nakatomi serves as the President of Hisamitsu Pharmaceutical Co. Inc. since May 2015 and has been Chief Executive Officer since May 2019 and has been Director since May 2007 and served as its...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kazuhide Nakatomi	President	9yrs	no data	0.32% ¥ 5.5m
Nobuo Tsutsumi	GM of Legal Dept	10yrs	no data	0.0053% ¥ 90.1k
Kazunori Ito	Executive Officer & GM of Human Resources Department	no data	no data	no data
Kyu Saito	MD, Executive Officer	no data	no data	0.0079% ¥ 135.2k
Shinichi Murayama	Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director	no data	no data	0.0066% ¥ 112.6k
Mitsutoshi Tsuruta	Executive Officer & Head of Ethical Division	no data	no data	no data
Masaya Okuno	Executive Officer and Head of Sales & Marketing Division	no data	no data	no data
Koji Takiyama	Executive Officer	3yrs	no data	0.0026% ¥ 45.1k
Katsuhiko Akiyama	Sr. Exe. Officer & GM of MN Commercialization Office	1.3yrs	no data	no data

6.0yrs

Average Tenure

56yo

Average Age

Experienced Management: HPX's management team is seasoned and experienced (6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Kazuhide Nakatomi	President	17yrs	no data	0.32% ¥ 5.5m
Nobuo Tsutsumi	GM of Legal Dept	10yrs	no data	0.0053% ¥ 90.1k
Kyu Saito	MD, Executive Officer	11yrs	no data	0.0079% ¥ 135.2k
Shinichi Murayama	Executive Officer of Mgmt. of Internal Audit Division & Domestic Subsidiary Division and Director	10yrs	no data	0.0066% ¥ 112.6k
Koji Takiyama	Executive Officer	3yrs	no data	0.0026% ¥ 45.1k
Munehiko Hirano	Standing Corporate Auditor	18yrs	no data	0.0026% ¥ 45.1k
Nobuyuki Nakatomi	Standing Corporate Auditor	16yrs	no data	0.36% ¥ 6.2m
Keinosuke Ono	Part-time Outside Corporate Auditor	no data	no data	0.0026% ¥ 45.1k
Tetsugo Matsuo	Part-time Outside Independent Director	4yrs	no data	0.0013% ¥ 22.5k
Teijiro Furukawa	Independent Outside Director	9yrs	no data	no data
Yuichiro Anzai	Part-time Outside Independent Director	4yrs	no data	no data
Tamako Watanabe	Part Time Outside Independent Director	less than a year	no data	no data

10.0yrs

Average Tenure

59.5yo

Average Age

Experienced Board: HPX's board of directors are seasoned and experienced ( 10 years average tenure).

Hisamitsu Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Full year 2024 earnings released: EPS: JP¥182 (vs JP¥148 in FY 2023)

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024

Upcoming dividend of JP¥42.50 per share

Third quarter 2024 earnings released: EPS: JP¥48.25 (vs JP¥37.89 in 3Q 2023)

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2024 Results on Jan 11, 2024

Second quarter 2024 earnings released: EPS: JP¥56.25 (vs JP¥61.11 in 2Q 2023)

New minor risk - Share price stability

Upcoming dividend of JP¥42.50 per share at 1.8% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2024 Results on Oct 06, 2023

First quarter 2024 earnings released: EPS: JP¥52.08 (vs JP¥20.46 in 1Q 2023)

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.57% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024

Full year 2023 earnings released: EPS: JP¥148 (vs JP¥119 in FY 2022)

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2024 Results on Jul 13, 2023

Full year 2023 earnings released: EPS: JP¥148 (vs JP¥119 in FY 2022)

Upcoming dividend of JP¥42.25 per share at 2.2% yield

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2023 Results on Apr 13, 2023

Third quarter 2023 earnings released: EPS: JP¥37.89 (vs JP¥14.91 in 3Q 2022)

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2023

Less than half of directors are independent

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2023 Results on Jan 12, 2023

Second quarter 2023 earnings released: EPS: JP¥61.11 (vs JP¥32.30 in 2Q 2022)

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,000,000 shares, representing 2.51% for ¥10,000 million.

Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter Ended August 31, 2022, Payable on Nov. 9, 2022; Provides Dividend Guidance for the full year ending February 28, 2023

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2023 Results on Oct 12, 2022

First quarter 2023 earnings released: EPS: JP¥20.46 (vs JP¥28.90 in 1Q 2022)

Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter and Full Year Ending February 28, 2023

Full year 2022 earnings released: EPS: JP¥119 (vs JP¥113 in FY 2021)

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2023 Results on Jul 07, 2022

Less than half of directors are independent

Full year 2022 earnings released: EPS: JP¥122 (vs JP¥113 in FY 2021)

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2023

Upcoming dividend of JP¥42.00 per share

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2022 Results on Apr 07, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Year Ending February 28, 2022

Second quarter 2022 earnings released: EPS JP¥32.30 (vs JP¥43.82 in 2Q 2021)

Upcoming dividend of JP¥42.00 per share

First quarter 2022 earnings released: EPS JP¥28.90 (vs JP¥1.38 in 1Q 2021)

Full year 2021 earnings released

Full year 2021 earnings released: EPS JP¥113 (vs JP¥228 in FY 2020)

Hisamitsu Pharmaceutical Co., Inc. Provides Earnings Guidance for the Year Ending February 28, 2022

Upcoming Dividend of JP¥41.75 Per Share

New 90-day high: €51.50

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2021 Results on Apr 08, 2021

Revenue misses expectations

Revenue misses expectations

Revenue misses expectations

Third quarter 2021 earnings released: EPS JP¥24.82

New 90-day high: €50.50

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2021 Results on Jan 13, 2021

New 90-day high: €46.40

First half earnings released

Semi-annual earnings released: Revenue misses expectations

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2021 Results on Oct 08, 2020

New 90-day low - €37.20

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age